Characteristics of patients initiating treatment with baricitinib and outcomes at follow-up: analysis of British Society for Rheumatology Biologics Registry-RA (BSRBR-RA) Registry data
Authors' conclusion
In the early years of real-world baricitinib use in the UK, a high proportion of patients continued with treatment at both 6 and 12 months, at which times disease activity was lower than at baseline.
Study context
- Population
- Patients initiating baricitinib for RA in a UK real-world rheumatology setting, 1 January 2018 to 31 March 202076.5% female
- Participants
- 561 patients
- Outcome
- Continuation of baricitinib treatment in patients with at least one follow-up
Methodological detailsreal-world, BSRBR-RA baricitinib cohort, Kaplan-Meier analyses
- Real-world
- BSRBR-RA baricitinib cohort
- Kaplan-Meier analyses
Main finding
As reported in the abstract
Remained on baricitinib
Remained on baricitinib at 6 months (of 265 completing follow-up with available data)
77.7%
Remained on baricitinib at 12 months (of 110 completing follow-up with available data)
69.1%
Remained on baricitinib at 540 days, all Kaplan-Meier analyses
>60%
Observational data: associations, not effects.
Further findings
Disease activity · 6 and 12 months
- Lower at both follow-ups than at baseline, overall and in all subgroups
Original publication
Characteristics of patients initiating treatment with baricitinib and outcomes at follow-up: analysis of BSRBR-RA Registry data. Rheumatology (Oxford). Published 24 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →